Exclusive: Is Buying Stock Like Cerus Corporation After Such Increase Winning Strategy?

Exclusive: Is Buying Stock Like Cerus Corporation After Such Increase Winning Strategy?

The stock of Cerus Corporation (NASDAQ:CERS) is a huge mover today! About 199,723 shares traded hands. Cerus Corporation (NASDAQ:CERS) has risen 4.80% since March 7, 2016 and is uptrending. It has underperformed by 2.80% the S&P500.
The move comes after 9 months positive chart setup for the $617.60 million company. It was reported on Oct, 10 by Barchart.com. We have $9.04 PT which if reached, will make NASDAQ:CERS worth $296.45 million more.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on November, 3. They expect $-0.16 earnings per share, up 5.88% or $0.01 from last year’s $-0.17 per share. After $-0.18 actual earnings per share reported by Cerus Corporation for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Out of 2 analysts covering Cerus (NASDAQ:CERS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cerus has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. On Tuesday, August 11 the stock rating was downgraded by Zacks to “Buy”. Wedbush downgraded the shares of CERS in a report on Thursday, December 17 to “Neutral” rating. On Wednesday, August 19 the stock rating was maintained by BTIG Research with “Buy”.

According to Zacks Investment Research, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.”

Insitutional Activity: The institutional sentiment decreased to 1.69 in Q2 2016. Its down 0.06, from 1.75 in 2016Q1. The ratio worsened, as 10 funds sold all Cerus Corporation shares owned while 26 reduced positions. 8 funds bought stakes while 53 increased positions. They now own 66.39 million shares or 1.07% more from 65.69 million shares in 2016Q1.
Great West Life Assurance Can holds 0% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 23,200 shares. Delta Lloyd Nv last reported 500,000 shares in the company. Citadel Advsrs Limited Liability Corporation reported 53,149 shares or 0% of all its holdings. Paradigm Asset Management Ltd Liability accumulated 114,700 shares or 0% of the stock. Millennium Limited Liability Corporation has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Susquehanna Intl Gp Llp has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). The New York-based Alliancebernstein Ltd Partnership has invested 0.02% in Cerus Corporation (NASDAQ:CERS). Amp Limited has 0% invested in the company for 35,400 shares. Northern Corporation accumulated 1.23M shares or 0% of the stock. Turner Investments Limited Partnership holds 0.12% or 60,000 shares in its portfolio. Goldman Sachs has 0% invested in the company for 73,019 shares. Lesa Sroufe And last reported 609,182 shares in the company. Brick And Kyle Associates has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Tiaa Cref Management Lc has 0% invested in the company for 440,105 shares. Bnp Paribas Arbitrage last reported 0% of its portfolio in the stock.

Insider Transactions: Since August 22, 2016, the stock had 0 insider buys, and 1 sale for $116,612 net activity. The insider Green Kevin Dennis sold $116,612.

More recent Cerus Corporation (NASDAQ:CERS) news were published by: Fool.com which released: “Cerus Corporation is Surging Today. Here’s Why.” on June 20, 2016. Also Businesswire.com published the news titled: “Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on October 05, 2016. Businesswire.com‘s news article titled: “Cerus Corporation Reports Second Quarter 2016 Results” with publication date: August 04, 2016 was also an interesting one.

CERS Company Profile

Cerus Corporation, incorporated on July 31, 1996, is a biomedical products company. The Firm is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Firm operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment